BOCA RATON, Fla., and HOBOKEN, N.J., October 14, 2026
INmune Bio Inc. (NASDAQ: INMB) and Quantum Computing Inc. (NASDAQ: QUBT) announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify potential new applications for XPro1595, INmune Bio’s investigational treatment for Alzheimer’s disease and other conditions. The collaboration combines INmune Bio’s preclinical research, clinical data from four trials and disease biology expertise with Quantum Computing Inc.’s Dirac-3S entropy quantum optimization machine. The companies plan to analyze clinical and publicly available biomedical datasets to identify relationships between disease biology, biomarkers and potential treatment responses. The initial engagement marks QCi’s first commercial customer relationship in the pharmaceutical and biotechnology sectors. The companies aim to identify diseases that share biological mechanisms targeted by XPro, prioritize promising indications and establish a repeatable computational discovery process to support future research and development decisions.
Quantum Optimization and AI to Identify New Treatment Opportunities
The collaboration will use quantum optimization alongside AI and conventional data analytics to examine complex clinical and biomedical datasets. INmune Bio will contribute its existing research on XPro1595, including information from preclinical studies and four clinical trials, while QCi will apply its Dirac-3S computing technology to search for patterns and relationships across the available data. The objective is to identify patient populations and biomarkers that may help predict treatment response, as well as diseases whose underlying biology aligns with XPro’s mechanism of action. INmune Bio Chief Executive Officer David Moss said the companies intend to prioritize indications with the greatest potential for successful development, beginning with rare diseases where trials may be smaller, faster and more capital-efficient. The announcement also notes the potential relevance of qualifying pediatric approvals that may provide access to a Priority Review Voucher. These are discovery and prioritization goals rather than established clinical outcomes. The companies will need to evaluate the resulting computational findings and determine which hypotheses warrant additional biological research and clinical investigation.
XPro1595 Targets Soluble TNF and Inflammation
XPro1595 is designed to selectively inhibit soluble tumor necrosis factor (TNF), an inflammatory protein implicated in several disease processes, while preserving other TNF functions considered important to immune system activity. INmune Bio is investigating this targeted approach in neurological and rare diseases where modulation of inflammation may offer therapeutic potential. In Alzheimer’s disease, the company is developing XPro1595 for neuroinflammation-enriched early-stage disease populations. Its broader strategy involves matching treatment mechanisms with patient biology to help identify populations that may be more likely to respond. The collaboration with QCi is intended to extend this approach by examining whether existing data can reveal additional disease indications and useful biomarkers. QCi Chairman and Chief Executive Officer Yuping Huang said the engagement will test how quantum computing can contribute to a complex scientific problem involving substantial clinical and biological information. The announcement does not report newly identified indications, validated biomarkers or clinical efficacy results from the collaboration. Instead, the work is intended to generate and prioritize research hypotheses that can be assessed through subsequent scientific and clinical studies.
Advertisement
Companies to Compare Quantum and Conventional Methods
An important component of the collaboration will be determining where quantum optimization provides practical value relative to established computational approaches. The companies plan to compare QCi’s quantum optimization results with appropriate conventional statistical and machine-learning methods to evaluate which techniques are best suited to different analytical tasks. This comparison is intended to help establish the potential contribution of quantum computing to pharmaceutical research rather than assuming an advantage in advance. The companies also aim to develop a repeatable discovery workflow that INmune Bio can apply to additional datasets and potential disease indications. For INmune Bio, the initiative provides another way to evaluate the broader development opportunities for XPro1595 and prioritize future research. For QCi, it represents an initial commercial application of its room-temperature, low-power quantum computing technology in the pharmaceutical and biotechnology industries. INmune Bio is a clinical-stage biotechnology company focused on treatments targeting the innate immune system. Alongside XPro1595, its development portfolio includes CORDStrom, an allogeneic umbilical cord-derived mesenchymal stromal cell platform being advanced for regulatory submissions. The new collaboration adds a computational discovery initiative to INmune Bio’s efforts to develop therapies for diseases with significant unmet medical needs.
Source::INmune Bio, press release
